Four-drug combination chemotherapy of carboplatin, pemetrexed, bevacizumab and erlotinib

2 trials

Sponsors

Kurata Takayasu, North East Japan Study Group (NEJSG)

Conditions

Non-small cell lung cancernon-squamous non-small cell lung cancer harboring EGFR active mutation

Phase 2

Phase II study of combination chemotherapy of Carboplatin, Pemetrexed, Bevacizumab and Erlotinib in patients with advanced non-squamous non-small cell lung cancer harboring EGFR active mutation.

Active, not recruitingJPRN-UMIN000029476

North East Japan Study Group (NEJSG)non-squamous non-small cell lung cancer harboring EGFR active mutation

Start: 2017-11-01Target: 35Updated: 2026-06-29

Phase II study of 4-drug combination chemotherapy in patients with non-small cell lung cancer harboring EGFR active mutation.

Active, not recruitingJPRN-jRCTs031180157

Kurata TakayasuNon-small cell lung cancer

Start: 2017-11-17Target: 35Updated: 2026-06-29